EFFECTS OF HBV SUBGENOTYPE A2 AND AN INITIAL 24-WEEK COURSE OF PEGINTERFERON ON OUTCOMES WITH LONGER-TERM TENOFOVIR: THE MULTICENTER HBRN IMMUNE ACTIVE (IA) TRIAL
HEPATOLOGY(2021)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined